I am passionate about supporting emerging companies and investors in cross-border transactions with my expertise and practical business judgment.

Passions

Reading

Tennis

Hiking

Dance

Key stats on Monica

800+

private financings completed for clients globally

1st

and afterwards investments in the PRC completed for many fund clients

Founding member of Cooley’s Shanghai office and the longest-serving attorney among Cooley Asia offices

Experience

ProfoundBio Announces $1.8 Billion Acquisition by Genmab

April 3, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Rowook Park
Partner, San Diego
Ruomu Li
Partner, Shanghai
Jenny Ge
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Barbara Mirza
Partner, Santa Monica
Sonia Nath
Partner, Washington, DC
Jean Park
Partner, New York
Lei Shen
Partner, Chicago
Stacey A. Bradford
Special Counsel, Washington, DC
Jeff Goldman
Special Counsel, Palo Alto
Amy Hallman Rice
Special Counsel, San Diego
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Andrew Bae
Associate, Washington, DC
Julia R. Brinton
Associate, Washington, DC
Megan Drill
Associate, San Diego
Mari Dugas
Associate, Washington, DC
Allison Kutner
Associate, New York
Jiqiang Lin
Associate, New York
Tyler Saavedra-Buckley
Associate, San Francisco
Ivy Wang
Associate, Shanghai
Monica Xu
Counsel, Shanghai
Freddy Yip
Associate, Hong Kong
Zhijing Yu
Associate, Singapore
Andy Zachrich
Associate, San Diego
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

ProfoundBio Announces $112 Million Oversubscribed Series B

February 14, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Read more

Related contacts

Patrick Loofbourrow
Partner, Singapore
Monica Xu
Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Zixiang Liu
Associate, Shanghai
Xander Lee
Partner, Santa Monica
Charlie Kim
Partner, San Diego
Christopher Kimball
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Sarah Oliai
Associate, Washington, DC
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

InxMed Raises $50 Million Series B

March 10, 2022

Cooley advised InxMed on its $50 million Series B financing. Partner Christina Zhang led the team advising InxMed, which is a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors.

CS Capital led the round, with participation from AIHC Fund, Growth Fund and Hosencare Fund, as well as existing investor Ennovation Ventures. InxMed will use the funds to accelerate ongoing clinical trials of IN10018 for multiple cancer types in the US and China, to advance more stroma-targeting pipelines into clinics this year, and to strengthen research and development capabilities in Nanjing, China.

Related contacts

Christina Zhang
Partner, Shanghai
Monica Xu
Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries

EpimAb Biotherapeutics Raises $120 Million Series C

March 23, 2021

Cooley advised EpimAb Biotherapeutics, a clinical-stage biotech company specializing in bispecific antibody development, on its $120 million Series C financing. China Merchants Bank International and Mirae Asset Financial Group co-led the round, which also included participation by Hony Capital, Cormorant Asset Management and other new investors, as well as existing investors such as Decheng Capital, SDIC Fund and Sherpa Healthcare Partners. EpimAb will use the new capital for the ongoing clinical development of three of its clinical assets and to expand its pipeline of novel bispecific antibodies and other biologics. Partner James Lu led the team advising EpimAb on the financing round.

Related contacts

Monica Xu
Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries

Crown Bioscience Enters Merger Agreement With JSR Corporation

September 11, 2019

Cooley advised the special committee of the board of directors of Crown Bioscience International, a global drug discovery and development services, company on its merger agreement with JSR Corporation, headquartered in Tokyo, Japan. The merger is expected to close before the end of second quarter of 2018.

Under the terms of the merger agreement, Crown Bioscience will merge into and become an indirect, wholly-owned subsidiary of JSR and be delisted from the Taipei Exchange. The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in vitro diagnostic solutions, GMP manufacturing capabilities and worldwide distribution networks.

“We are excited to join the JSR family of companies through this innovation-driven strategic partnership,” said Dr. Jean-Pierre Wery, Crown Bioscience’s CEO. “Crown Bioscience’s core competencies in preclinical and translational research combined with JSR’s global footprint, diagnostic solutions and manufacturing capabilities will provide a fully integrated solution to help biopharmaceutical companies get drugs and diagnostics to market more efficiently.”

Crown Bioscience, which trades on the Taipei Exchange under the ticker “6554,” is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Related contacts

Rama Padmanabhan
Partner, San Diego
Paul Roberts
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Kevin King
Partner, Washington, DC
Howard Morse
Partner, Washington, DC
Thomas Welk
Senior Counsel, San Diego
Lois Voelz
Senior Counsel, Palo Alto
Rebecca Ross
Special Counsel, Washington, DC
Christopher Kimball
Partner, Washington, DC
Andrew Harline
Partner in Charge – Singapore, Singapore
Edmond Lay
Associate, San Diego
Stuyvie Pyne
Special Counsel, New York
Monica Xu
Counsel, Shanghai
Chris Stack
Partner, London

Related Practices & Industries

Admissions and credentials

New York

People's Republic of China